Delpharm has grown through the acquisition of plant from major big pharmas. With more than 900 million units produced per year in a wide range of dosage forms, Delpharm is among the key drug manufacturers in the world. All the more, Delpharm is fully dedicated to pharma services for others : 100% of the turnover is for manufacturing and development for its customers. Priority is always given to customers.
In 2022, Delpharm was able to acquire the Boucherville (Canada) plant, which was owned by Novartis.
This plant allows Delpharm to offer sterile ampoules and vials in North America.
In 2021, Delpharm was able to acquire Poznań plant, which was owned by GSK. This one allows Delpharm to add a new offer in the company’s portfolio: high potent soft gel capsules.2021
Creation of DELPHARM ACADEMY
DELPHARM ACADEMY’s objectives are to organise:
- The integration of our new employees, then to encourage them in their professional development and to develop their technical expertise.
- The training of our future employees in our professions.
Delpharm has been recognized by several Labels in terms of human resources.
Delpharm : Employment creator
Since the creation of the company, 630 employees have joined the Delpharm adventure at these 17 plants.2019
Acquistion of 5 new plants
2019 is a major year for Delpharm with the acquistion of 5 new plants from Famar.
Each plant has its strong asset:
- Delpharm Bladel expands the company’s capabilities in liquid and semi-solid forms.
- Delpharm L’Aigle allows the increase of capabilities in solid forms and more specifically sugar-coated tablets.
- Delpharm Montréal is the first plant in North America.
- Delpharm Orléans is a plant with more capabilities in effervescent tablets, sachets and liquid and semi-solid forms in mass production.
- Delpharm Saint-Rémy provides a new dosage form to the group: freeze-drying.2019
Delpharm attends for the first time to DCAT Week which is the premier business development event for companies engaged in pharmaceutical development and manufacturing and related industries.2017
Delpharm grows up in Italy with the acquisition of Roche Segrate plant in Milano. This one allows Delpharm to export conventional solid forms to USA with FDA agreement.2017
In June 2016, Delpharm Evreux starts softgel capsules production and creates 5 new jobs for this new dosage forms.2016
The year 2016 allows Delpharm to acquire its second European plant, based in Novara with a new offer in the company’s portfolio: prefilled syringes packaging.2016
Delpharm moves to a new headquarter in Boulogne-Billancourt (92100).2015
In 2015, Delpharm increases its injectables capacities thanks to Dijon plant, previously owned by Sanofi.2015
Delpharm develops its activities and offer with the development and manufacturing of biotechnologies within the Lyon plant, ex Pfizer.2013
In 2012, Delpharm has the opportunity to acquire Gaillard plant, which was owned by Bayer. This plant allows the company to develop his galenical portfolio with effervescent tablets.2012
Drogenbos Plant, ex Besins, is the first European plant acquired by Delpharm, based in Belgium. The plant is a center of excellence for sexual hormonal products.2012
Huningue plant acquisition, ex Novartis, allows Delpharm to propose semi-solids forms and more.2011
Delpharm Lille obtains FDA approval for the first time.2010
In 2008, Delpharm expands the dosage forms range with the acquisition of Boehringer plant, based in Reims. The company adds liquid forms to its portfolio.2008
Bayer Schering plant becomes Delpharm Lille in 2006 with hormones and high potent forms as core business.2006
In 2002, the company acquires Evreux plant, ex Pfizer Pharmaceutical, allowing it to increase its solid forms capacities.2002
In 1994, Delpharm make the acquisition of Brétigny plant, ex Roche Synthex, which is specialised in solid forms.1994
Delpharm was funded by the acquisition of Tours plant which belonged to Delmas. The first dosage forms obtained by the group was injectables.1988